Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

LPA3 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Validation of the Lysophosphatidic Acid Receptor 3 in transfected HEK293 cells
LPA3 (non-phospho), Lysophosphatidic Acid...
The non-phospho-LPA3 receptor antibody is directed against the distal end of the carboxyl-terminal tail of human LPA3. It can be used to detect total LPA3 receptors in Western blots independent of phosphorylation. The LPA3 antibody can...
375.00 € *
Details

The lysophosphatidic acid receptor 3 (LPA₃), encoded by the LPAR3 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) with high affinity. LPA₃ primarily couples to Gq/11 and Gi/o proteins, activating downstream signaling cascades such as phospholipase C (PLC), intracellular calcium mobilization, MAPK/ERK, and PI3K/Akt, which regulate cell proliferation, migration, and survival. LPA₃ is expressed in reproductive tissues including the ovary, uterus, and testis, as well as in the heart, liver, and certain immune cells, suggesting roles in both developmental and physiological processes. Functionally, LPA₃ is critical for reproductive biology, influencing ovulation, embryo implantation, and early pregnancy, and also contributes to cell motility, inflammation, and tissue remodeling in other contexts. Dysregulated LPA₃ signaling has been linked to cancer progression, particularly in breast, ovarian, and prostate cancers, where it promotes tumor cell migration, invasion, and metastasis. Pharmacologically, selective LPA₃ agonists and antagonists have been developed to dissect its functions and as potential therapeutic agents for fertility regulation and cancer treatment. LPA₃ also interacts with PDZ-domain proteins, which modulate receptor localization and signaling specificity. Overall, LPA₃ functions as a lipid-sensing receptor that integrates reproductive, developmental, and pathological signaling, making it a key target in fertility, oncology, and tissue repair research. For more information on LPA3 pharmacology please refer to the IUPHAR database. For further reading refer to:

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111. PMID: 21079037; PMCID: PMC2993255.

Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12. PMID: 24602016; PMCID: PMC4128058.

Blaho V, Chun J, Herr D, Jones D, Jonnalagadda D, Kihara Y. Lysophospholipid (S1P) receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

The lysophosphatidic acid receptor 3 (LPA₃), encoded by the LPAR3 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) with high... read more »
Close window
LPA3 Receptor Antibodies

The lysophosphatidic acid receptor 3 (LPA₃), encoded by the LPAR3 gene, is a class A G protein–coupled receptor (GPCR) that binds the bioactive lipid lysophosphatidic acid (LPA) with high affinity. LPA₃ primarily couples to Gq/11 and Gi/o proteins, activating downstream signaling cascades such as phospholipase C (PLC), intracellular calcium mobilization, MAPK/ERK, and PI3K/Akt, which regulate cell proliferation, migration, and survival. LPA₃ is expressed in reproductive tissues including the ovary, uterus, and testis, as well as in the heart, liver, and certain immune cells, suggesting roles in both developmental and physiological processes. Functionally, LPA₃ is critical for reproductive biology, influencing ovulation, embryo implantation, and early pregnancy, and also contributes to cell motility, inflammation, and tissue remodeling in other contexts. Dysregulated LPA₃ signaling has been linked to cancer progression, particularly in breast, ovarian, and prostate cancers, where it promotes tumor cell migration, invasion, and metastasis. Pharmacologically, selective LPA₃ agonists and antagonists have been developed to dissect its functions and as potential therapeutic agents for fertility regulation and cancer treatment. LPA₃ also interacts with PDZ-domain proteins, which modulate receptor localization and signaling specificity. Overall, LPA₃ functions as a lipid-sensing receptor that integrates reproductive, developmental, and pathological signaling, making it a key target in fertility, oncology, and tissue repair research. For more information on LPA3 pharmacology please refer to the IUPHAR database. For further reading refer to:

Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec;62(4):579-87. doi: 10.1124/pr.110.003111. PMID: 21079037; PMCID: PMC2993255.

Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014 Aug;171(15):3575-94. doi: 10.1111/bph.12678. Epub 2014 Jul 12. PMID: 24602016; PMCID: PMC4128058.

Blaho V, Chun J, Herr D, Jones D, Jonnalagadda D, Kihara Y. Lysophospholipid (S1P) receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1).

Recently viewed